PORTIA-21 Drug Patent Profile
✉ Email this page to a colleague
When do Portia-21 patents expire, and what generic alternatives are available?
Portia-21 is a drug marketed by Barr and is included in one NDA.
The generic ingredient in PORTIA-21 is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
Summary for PORTIA-21
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 5 |
Clinical Trials: | 7 |
Patent Applications: | 339 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PORTIA-21 at DailyMed |
Recent Clinical Trials for PORTIA-21
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
ViiV Healthcare | Phase 1 |
Pfizer | Phase 1 |
Columbia University | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for PORTIA-21
US Patents and Regulatory Information for PORTIA-21
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Barr | PORTIA-21 | ethinyl estradiol; levonorgestrel | TABLET;ORAL-21 | 075866-001 | May 23, 2002 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |